Teachers Retirement System of The State of Kentucky trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 3.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 285,758 shares of the company’s stock after selling 9,849 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Merck & Co., Inc. were worth $41,524,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also made changes to their positions in the company. Warner Group LLC bought a new position in shares of Merck & Co., Inc. during the 3rd quarter valued at $418,000. Western Wealth Management LLC lifted its stake in shares of Merck & Co., Inc. by 1.7% in the 3rd quarter. Western Wealth Management LLC now owns 32,215 shares of the company’s stock valued at $4,681,000 after purchasing an additional 552 shares during the last quarter. Francis Financial Inc. lifted its stake in shares of Merck & Co., Inc. by 23.4% in the 3rd quarter. Francis Financial Inc. now owns 2,412 shares of the company’s stock valued at $351,000 after purchasing an additional 457 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc boosted its holdings in Merck & Co., Inc. by 6.8% in the third quarter. Texas Capital Bank Wealth Management Services Inc now owns 20,358 shares of the company’s stock worth $2,958,000 after purchasing an additional 1,305 shares in the last quarter. Finally, Alaska Wealth Advisors LLC bought a new stake in Merck & Co., Inc. in the third quarter worth $233,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Merck & Co., Inc.
In other news, EVP Richard Deluca sold 58,185 shares of the firm’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $148.01, for a total value of $8,611,961.85. Following the sale, the executive vice president directly owned 112,955 shares of the company’s stock, valued at approximately $16,718,469.55. This trade represents a 34.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.17% of the stock is owned by company insiders.
Merck & Co., Inc. Price Performance
Shares of Merck & Co., Inc. stock opened at $144.49 on Tuesday. The company has a current ratio of 1.35, a quick ratio of 1.14 and a debt-to-equity ratio of 1.11. The firm has a fifty day simple moving average of $146.04 and a 200-day simple moving average of $128.80. The stock has a market capitalization of $356.20 billion, a price-to-earnings ratio of 148.96, a PEG ratio of 6.74 and a beta of 0.13. Merck & Co., Inc. has a 1-year low of $92.11 and a 1-year high of $156.92.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. The business had revenue of $18.09 billion for the quarter, compared to analyst estimates of $17.33 billion. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. Merck & Co., Inc.’s revenue was up 4.7% compared to the same quarter last year. During the same period last year, the business posted $2.58 EPS. On average, sell-side analysts expect that Merck & Co., Inc. will post 2.82 earnings per share for the current year.
Analyst Upgrades and Downgrades
MRK has been the topic of several analyst reports. Guggenheim increased their target price on shares of Merck & Co., Inc. from $170.00 to $171.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Leerink Partners boosted their price target on Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. Morgan Stanley reduced their price target on Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research report on Wednesday, October 7th. Citigroup upped their price target on Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a research note on Monday, October 12th. Finally, Berenberg Bank increased their price objective on Merck & Co., Inc. from $127.00 to $137.00 and gave the company a “hold” rating in a report on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $155.74.
Merck & Co., Inc. Company Profile
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
See Also
- Five stocks we like better than Merck & Co., Inc.
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
